On June 19, 2025, at the headquarters building of Douzheng Biotechnology in Changsha, Lishan Biotech and leading domestic CRO enterprise Douzheng Biotechnology officially reached a strategic cooperation to jointly promote the clinical trials of Lishan Biotech's independently developed live biopharmaceutical (LBP) in the field of inflammatory bowel disease (IBD). This cooperation marks a new stage in the clinical exploration of live biopharmaceutical therapy, which is expected to provide safer and more effective innovative therapies for IBD patients worldwide.

Innovative treatment for IBD using LBP biopharmaceuticals

Live Biotherapeutic Products (LBP) is an emerging therapy that utilizes live microorganisms to regulate the human microbiota for the treatment of diseases, and is considered the "third generation therapy" after small molecule and antibody drugs. Inflammatory bowel disease (IBD) includes ulcerative colitis and Crohn's disease, and traditional treatment methods have problems such as insufficient response rate and high side effects. However, LBP, through targeted regulation of gut microbiota, is an innovative therapy that has the potential to fundamentally improve disease progression. Lishan Biotechnology, with a strong foundation in microbiome research and industrial experience, has successfully isolated over 1000 functional strains with clear therapeutic potential and established a production process that meets GMP standards. This collaboration with Douzheng Biotechnology will accelerate the clinical translation process of its LBP pipeline.

The complementary advantages of "pharmaceutical companies+CRO" create a collaborative research and development paradigm

Lishan Biotech has the full chain capability from strain discovery to production process in the LBP field. Its core advantages include exclusive invention patent "Biophysics Swarming Microbial Movement Mechanism - Intestinal Mucosal Repair Technology Based on Swarming Bacteria", exclusive functional strain library, covering multiple types of active strains such as anti-inflammatory and immune regulation; Breaking through the technological barriers of industrialization, key technologies for LBP production such as anaerobic cultivation and freeze-drying protection have been developed. As a leading enterprise in integrated research and development services CRO, Douzheng Biotechnology has rich experience in clinical trial design, execution, and regulatory registration, especially in optimizing clinical protocols and multi center management for complex indications such as IBD. The cooperation between the two parties will significantly shorten the research and development cycle and improve the efficiency of drug development.

Dr. Chen Weijie, Chairman of Lishan Biomedical

Dr. Chen Weijie, Chairman of Lishan Biopharmaceutical, stated that the clinical translation of LBP requires interdisciplinary collaboration. Du Zheng Biotechnology's professional capabilities and efficient execution in clinical trials will help us quickly verify the safety and effectiveness of the product, and benefit patients as soon as possible. Our collaboration can maximize efficiency, accelerate the process of drug development, achieve historic breakthroughs through close strategic cooperation, and continuously explore its clinical translation to create new history.

Dr. Ouyang Dongsheng, Chairman of Duzheng Biotechnology

Dr. Ouyang Dongsheng, Chairman of Duzheng Biotechnology, stated that Duzheng is honored to collaborate with Lishan Biotech as a pioneering enterprise in the field of live biological LBP. This project is not only a deep collaboration between CRO and pharmaceutical companies, but also an important practice of LBP's innovative drug research and development model. In the future, we also plan to expand the application of LBP in other indications such as metabolic diseases and tumor immunotherapy, and continue to lead the innovation of microbiota therapy.

This conference also gathered in-depth insights from multiple experts: Professor Mo Long discussed the latest progress in aging mechanism research and clinical applications under the title of "Clinical Aging Assessment and Intervention"; Professor Yang Jianbo, Chief Expert of Duzheng Inspection, reported on a study titled "A Novel NK Cell Engager CSPG4 TriKE: from Bench Research to Anticancer Immunotherapy", showcasing an innovative anti-cancer immunotherapy that has been transformed from basic to clinical use; Professor Zhang Wei elaborated on "Microbiomics and Individualized Medication", emphasizing the key role and development prospects of the microbiome in precision medicine; Chen Weijie, Chairman of Lishan Biotech, shared "Bacterial Swarmer and Its Application in IBD", introducing bacterial swarm behavior and its exploration in the treatment of inflammatory bowel disease.

About Lishan Biotech

Lishan Biotech was founded in 2022 and is an innovative enterprise dedicated to the research and industrialization of live biopharmaceuticals (LBP). Lishan Pharmaceutical utilizes its profound foundation in microbiome research and industrialization experience to develop live biopharmaceuticals, which regulate the human microbiota to treat diseases and provide safer and more effective drugs for patients worldwide.

About Duzheng Biology

Founded in 2016, Duzheng Biotechnology integrates "production, learning, and research" to provide technical services such as clinical research, pharmaceutical research and development informatization, and medical testing. Duzheng Biotechnology, with the mission of "serving the country and sharing its worries", has established a "one-stop" digital intelligent clinical research platform, creating an industrial ecosystem from service to "data" and from "data" to innovation, promoting the "industrial digitization" and "digital industrialization" in the field of life and health, and contributing to the cause of human health.

Fan Jincheng, Vice President and Director of the Health Special Committee of the Shanghai Modern Service Industry Federation, Wang Zhenggang, Deputy Director, Mo Long, Vice President of Xiangya Hospital of Central South University, Zhang Wei, Executive Deputy Director of the Clinical Pharmacology Research Institute of Xiangya Hospital of Central South University, Chen Xiaoping, Professor of the Clinical Pharmacology Research Institute of Xiangya Hospital of Central South University, and Zhou Yongbo, Professor of the School of Chemistry and Chemical Engineering of Hunan University, attended the signing meeting.